NEW YORK (GenomeWeb) – Cowen and Company on Friday upgraded GenMark Diagnostics to Outperform from Market Perform, lifting the company's shares for the second trading day in a row.

Cowen analyst Doug Schenkel said that recent "channel checks" suggest GenMark's ePlex molecular diagnostics system is doing well at early adopter sites in the EU, and that clinical trials for the test are likely to begin soon in the US.

"We've always liked the market opportunity, and after a long history of delays, ePlex finally appears ready to go," Schenkel wrote in a research note.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.